ReviewJournal of clinical medicine2023
Standard Bismuth Quadruple Therapy versus Concomitant Therapy for the First-Line Treatment of
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- AdjuvantMicrobiology spectrum · 2026Trial
- Review
- Effectiveness and Safety of First-Line Empirical Eradication Therapy with Rebamipide: Results from the European Registry onAntibiotics (Basel, Switzerland) · 2026Article
- Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice.Alimentary pharmacology & therapeutics · 2026Review
- Navigating the gastric frontier of mucosal immunity againstFrontiers in immunology · 2026Review
- Comparison of bismuth and concomitant therapy forFuture science OA · 2025Article
- Tegoprazan-Amoxicillin Dual Therapy for Clarithromycin-ResistantMicroorganisms · 2025Article
- Comparative Efficacy of Triple Versus Quadruple Therapy for the Eradication ofJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Tailored Therapy vs. Empirical Therapy forJournal of personalized medicine · 2025Review
- Diagnosis and treatment ofFuture microbiology · 2025Review
- The Prevalence ofEpidemiologia (Basel, Switzerland) · 2025Review
- Do the new ACGJournal of the Canadian Association of Gastroenterology · 2025Article
- Review
- Efficacy and Safety of Modified Bismuth Quadruple Therapy for First-LineMicroorganisms · 2025Review
- TargetingFrontiers in cellular and infection microbiology · 2025Article
- Therapeutic regimens againstTherapeutic advances in gastroenterology · 2025Article
- Review
- A Randomized, Prospective and Crossover Study, Comparing the Eradication Rate After 10 Days of Concomitant Therapy to Bismuth Quadruple Therapy Among a Sample of the Lebanese Population.Current therapeutic research, clinical and experimental · 2025Article
- Development of a High-Resolution Melting Method for the Detection of Clarithromycin-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Concomitant and Bismuth Quadruple Therapy forAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: Whether standard bismuth quadruple therapy (BQT) is superior to concomitant therapy for the first-line treatment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.